Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 + Chemotherapy in Second-Line Advanced or Metastatic Pancreatic Cancer
NCT07342725Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
01
Overview
A Phase 2 trial of IBI363 in pancreatic cancer (PC), sponsored by Ruijin Hospital. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
IBI363
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07342725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342725.